Unusual Drug Slows Development of Diabetic Kidney Disease

Unusual Drug Slows Development of Diabetic Kidney Disease

For sufferers with diabetic kidney illness, finerenone, an agent from a unusual class of selective, nonsteroidal mineralocorticoid receptor antagonists, led to necessary reductions in blended harmful renal outcomes and in blended harmful cardiovascular outcomes within the pivotal FIDELIO-DKD trial. And…